Drug Trial Radar · NCT06549595
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,018
Planned (sponsor's estimate)
Start
Aug 7, 2024
Primary completion
Nov 26, 2031
Study completion Nov 26, 2031
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard immunochemotherapy regimen, conducted in participants with untreated FL.
Conditions
- Untreated Follicular Lymphoma
Interventions
SurovatamigDrug
a fully human bispecific monoclonal IgG4 antibody
R-CHOPDrug
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
R-CVPDrug
Rituximab, Cyclophosphamide, Vincristine and Prednisone
BRDrug
Bendamustine, Rituximab
Primary outcomes
What the sponsor says the trial is designed to measure.
- SRI Primary: Incidence, nature and severity of AEs and SAEs. Incidence and nature of study drug discontinuations, dose reductions, and dose delays due to AEsTime frame: Up to 10 years
- SRI Primary: Determination of the recommended Phase III dose (RP3D)Time frame: Up to 1 year
- Phase 3 Dual Primary: To demonstrate the superiority of Surovatamig plus rituximab compared to Investigator's choice of SoC chemoimmunotherapyTime frame: Up to 10 years
- Phase 3 Dual Primary: To demonstrate the superiority of Surovatamig plus rituximab compared to Investigator's choice of SoC chemoimmunotherapyTime frame: Up to 10 years
Locations
244 sites in 25 countries. Site status is shown where the registry gives one.
Research Site
Huntsville, Alabama · Recruiting
Research Site
Anchorage, Alaska · Recruiting
Research Site
Phoenix, Arizona · Recruiting
Research Site
Clovis, California · Not yet recruiting
Research Site
Los Alamitos, California · Recruiting
Research Site
San Diego, California · Not yet recruiting
Research Site
Santa Monica, California · Not yet recruiting
Research Site
Aurora, Colorado · Withdrawn
Research Site
New Haven, Connecticut · Recruiting
Research Site
Newark, Delaware · Not yet recruiting
Research Site
Jacksonville, Florida · Recruiting
Research Site
Atlanta, Georgia · Not yet recruiting
Research Site
Macon, Georgia · Recruiting
Research Site
Evanston, Illinois · Not yet recruiting
Research Site
Peoria, Illinois · Not yet recruiting
Research Site
Fort Wayne, Indiana · Recruiting
Research Site
Des Moines, Iowa · Not yet recruiting
Research Site
Iowa City, Iowa · Not yet recruiting
Research Site
Lexington, Kentucky · Not yet recruiting
Research Site
Louisville, Kentucky · Not yet recruiting
Research Site
Baton Rouge, Louisiana · Not yet recruiting
Research Site
Baltimore, Maryland · Not yet recruiting
Research Site
Bethesda, Maryland · Recruiting
Research Site
Columbia, Maryland · Not yet recruiting
Research Site
Boston, Massachusetts · Not yet recruiting
Research Site
Boston, Massachusetts · Not yet recruiting
Research Site
Ann Arbor, Michigan · Not yet recruiting
Research Site
Detroit, Michigan · Withdrawn
Research Site
Ypsilanti, Michigan · Not yet recruiting
Research Site
Rochester, Minnesota · Recruiting
Research Site
Saint Paul, Minnesota · Not yet recruiting
Research Site
Chesterfield, Missouri · Not yet recruiting
Research Site
Springfield, Missouri · Recruiting
Research Site
Hackensack, New Jersey · Not yet recruiting
Research Site
New Brunswick, New Jersey · Not yet recruiting
Research Site
Albany, New York · Recruiting
Research Site
Brooklyn, New York · Not yet recruiting
Research Site
Mineola, New York · Not yet recruiting
Research Site
New Hyde Park, New York · Not yet recruiting
Research Site
New York, New York · Recruiting
Showing 40 of 244 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.